Ceballos-López AA, Saldaña-Vázquez R, Pequeño-Luévano MP, Salazar-Riojas MR, Méndez-Ramírez N, Reyes-López MA, Gómez-Almaguer D

Language: Spanish
References: 12
Page: 95-98
PDF size: 475.41 Kb.

ABSTRACT

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis.
Objective: Report laboratory tests results related to PNH diagnosis at a reference hospital in the Northeast of México.
Material and method: Retrospective study of results of patients suspected with PNH who underwent four-color cytofluorometry based on detection of CD55, CD59, CD45, CD14 and CD16 at our laboratory from January 2005 to May 2012. An analysis of available demographic variables was performed.
Results: 95 patients—34 (35.7%) males, 53 (55.7%) females and 8 (8.6%) of unknown sex were included in the study. Median age was 38 years; a minimum of a year and up to 87 years. Of the 95 samples, 11 (11.5%) were positive, 82 (86.3%) negative and 2 (2.1%) indeterminate.
Conclusions: A low percentage of positive test results was found even in patients with suspected diagnosis of PNH. The four-color cyto-fluorometry is a useful diagnostic tool for this disease.

REFERENCES

1. Madkaikar M, Gupta M, Jijina F, Ghosh K. Paroxysmal nocturnal haemoglobinuria: diagnostic tests, advantages, & limitations. Eur J Haematol 2009;83(6):503-511.

2. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry Part B. Clinical Cytometry 2012;82B:195-208.

3. Parker, C. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012,19:141-148.

4. Dunn DE, Liu JM, Young NS. Bone marrow failure in PNH. En: Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol- linked proteins. San Diego: Academic Press; 2000;113-138.

5. Britta Höchsmann, Markus Rojewski, Hubert Schrezenmeier. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann Hematol 2011;90:887-899.

6. Hillmen P, Hows JM, Luzzatto L (1992) Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol;80(3):399-405.

7. De Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, Roth S, de Guibert S, Maury S, Cahn JY, Socie G (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood112:3099-3106.

8. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in PNH. Blood 2003;102:3587-3591.

9. Sutherland DR, Kuek N, Azcona-Olivera J, Anderson T, Acton E, Barth D, Keeney M. Use of a FLAER-based WBC assay in the primary screening of PNH clones. Am J Clin Pathol 2009;132:564-572.

10. Borowitz MJ, Craig FE, DiGiuseppe JA, Illingworth AJ, Rosse W, Sutherland DR, Wittwer CT, Richards SJ. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom Part B Clin Cytom 2010;78B:211-230.

11. Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000;114:459-466.

12. Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, Bamford S, Chin-Yee I, Keeney M. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom 2007;72:167-177.